Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2549 USD | +1.92% | +35.59% | +2.08% |
May. 15 | ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 15 | Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024 |
Financials (USD)
Sales 2024 * | 9.99M | Sales 2025 * | 11.99M | Capitalization | 5.98M |
---|---|---|---|---|---|
Net income 2024 * | -6M | Net income 2025 * | -5M | EV / Sales 2024 * | 0.6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.5 x |
P/E ratio 2024 * |
-0.57
x | P/E ratio 2025 * |
-0.71
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.83% |
Latest transcript on ReShape Lifesciences Inc.
1 day | +1.92% | ||
1 week | +35.59% | ||
1 month | +45.41% | ||
3 months | +46.58% | ||
6 months | +9.54% | ||
Current year | +2.08% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Hickey
CEO | Chief Executive Officer | 59 | 20-01-31 |
Director of Finance/CFO | 63 | 21-06-14 | |
Dov Gal
CMP | Compliance Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Blackford
BRD | Director/Board Member | 66 | 15-12-31 |
Dan Gladney
CHM | Chairman | 70 | 15-10-31 |
Director/Board Member | 70 | 21-06-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.2549 | +1.92% | 4,594,550 |
24-05-30 | 0.2501 | -10.68% | 12,278,933 |
24-05-29 | 0.28 | +34.74% | 212,545,021 |
24-05-28 | 0.2078 | +10.53% | 64,674,825 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.08% | 5.98M | |
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+30.79% | 111B | |
+1.48% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.6B |
- Stock Market
- Equities
- RSLS Stock